An immune risk score predicts survival of patients with diffuse large B-cell lymphoma

Shankland, 2012, Non-Hodgkin lymphoma, Lancet, 380, 848, 10.1016/S0140-6736(12)60605-9 Armitage, 2017, Non-Hodgkin lymphoma, Lancet, 390, 298, 10.1016/S0140-6736(16)32407-2 Lange, 2017, Mature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications, Expert Rev. Hematol., 10, 123, 10.1080/17474086.2017.1271318 P. International Non-Hodgkin's Lymphoma Prognostic Factors, 1993, A predictive model for aggressive non-Hodgkin's lymphoma, N. Engl. J. Med, 329, 987, 10.1056/NEJM199309303291402 Abramson, 2020, Anti-CD19 CAR T-cell therapy for B-cell non-hodgkin lymphoma, Transfus. Med Rev., 34, 29, 10.1016/j.tmrv.2019.08.003 Roselli, 2021, Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes, J. Clin. Invest, 131, 10.1172/JCI142030 Sanmamed, 2018, A paradigm shift in cancer immunotherapy: from enhancement to normalization, Cell, 175, 313, 10.1016/j.cell.2018.09.035 Finotello, 2018, Quantifying tumor-infiltrating immune cells from transcriptomics data, Cancer Immunol. Immunother., 67, 1031, 10.1007/s00262-018-2150-z Newman, 2019, Determining cell type abundance and expression from bulk tissues with digital cytometry, Nat. Biotechnol., 37, 773, 10.1038/s41587-019-0114-2 Newman, 2015, Robust enumeration of cell subsets from tissue expression profiles, Nat. Methods, 12, 453, 10.1038/nmeth.3337 Zeng, 2018, Gene expression profiles for a prognostic immunoscore in gastric cancer, Br. J. Surg., 105, 1338, 10.1002/bjs.10871 Zhou, 2019, Immune cell infiltration as a biomarker for the diagnosis and prognosis of stage I-III colon cancer, Cancer Immunol. Immunother., 68, 433, 10.1007/s00262-018-2289-7 Cioroianu, 2019, Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Role and Prognosis, Anal. Cell Pathol. (Amst. ), 2019, 8586354 Xu-Monette, 2019, Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL, Cancer Immunol. Res, 7, 644, 10.1158/2326-6066.CIR-18-0439 Walunas, 1994, CTLA-4 can function as a negative regulator of T cell activation, Immunity, 1, 405, 10.1016/1074-7613(94)90071-X Freeman, 2000, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J. Exp. Med, 192, 1027, 10.1084/jem.192.7.1027 Latchman, 2001, PD-L2 is a second ligand for PD-1 and inhibits T cell activation, Nat. Immunol., 2, 261, 10.1038/85330 Samoszuk, 1997, Eosinophils and human cancer, Histol. Histopathol., 12, 807 Boutilier, 2021, Macrophage polarization states in the tumor microenvironment, Int J. Mol. Sci., 22, 10.3390/ijms22136995 Irikura, 2009, Biochemical, functional, and pharmacological characterization of AT-56, an orally active and selective inhibitor of lipocalin-type prostaglandin D synthase, J. Biol. Chem., 284, 7623, 10.1074/jbc.M808593200 Shimanuki, 2012, Lipocalin-type prostaglandin D synthase as a marker for the proliferative potential of melanocyte-lineage cells in the human skin, J. Dermatol., 39, 699, 10.1111/j.1346-8138.2011.01485.x Nault, 2018, Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas, Hepatology, 68, 964, 10.1002/hep.29884 Kim, 2005, Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products, Cancer Res, 65, 6189, 10.1158/0008-5472.CAN-04-4439 Ragolia, 2010, Diminished lipocalin-type prostaglandin D(2) synthase expression in human lung tumors, Lung Cancer, 70, 103, 10.1016/j.lungcan.2010.01.011 Zhang, 2018, PGD2/PTGDR2 Signaling Restricts the Self-Renewal and Tumorigenesis of Gastric Cancer, Stem Cells, 36, 990, 10.1002/stem.2821 Fukuoka, 2015, Prostaglandin D synthase is a potential novel therapeutic agent for the treatment of gastric carcinomas expressing PPARgamma, Int J. Cancer, 137, 1235, 10.1002/ijc.29392 Hu, 2022, Glycoprotein PTGDS promotes tumorigenesis of diffuse large B-cell lymphoma by MYH9-mediated regulation of Wnt-beta-catenin-STAT3 signaling, Cell Death Differ., 29, 642, 10.1038/s41418-021-00880-2 Ma, 2021, A prognostic immune risk score for diffuse large B-cell lymphoma, Br. J. Haematol., 194, 111, 10.1111/bjh.17478 Scott, 2014, The tumour microenvironment in B cell lymphomas, Nat. Rev. Cancer, 14, 517, 10.1038/nrc3774 Hopken, 2019, Targeting the tumor microenvironment of leukemia and lymphoma, Trends Cancer, 5, 351, 10.1016/j.trecan.2019.05.001